AC vs TC Chemotherapy: Mechanisms, Timeline, and Side Effect Differences

AC and TC are two adjuvant chemotherapy regimens for early breast cancer, and the core difference is drug class: AC pairs an anthracycline (doxorubicin or epirubicin) with cyclophosphamide, while TC pairs a taxane (docetaxel) with cyclophosphamide. AC is typically given every 2 or 3 weeks for 4 cycles (about 8 to 12 weeks total), whereas TC is given every 3 weeks for 4 cycles (about 12 weeks). Both are used mainly after surgery in node-negative or low-node-burden, HER2-negative disease; anthracycline-based AC remains preferred when high-risk features are present.

What AC and TC actually are

AC is a two-drug backbone built on an anthracycline. The "A" is doxorubicin 60 mg/m² (or epirubicin 90 to 100 mg/m² in European regimens), and the "C" is cyclophosphamide 600 mg/m². Both are given intravenously on day 1 of each cycle. The regimen runs for four cycles, spaced either 14 days apart (dose-dense) or 21 days apart.

TC substitutes the anthracycline for a taxane. The standard version is docetaxel 75 mg/m² plus cyclophosphamide 600 mg/m², again on day 1, every 21 days for four cycles. Some protocols use a 75/600 split while others use 75/600 on a 3-week cadence; the four-cycle structure is the near-universal constant.

The naming convention confuses many people because acetylcholinesterase inhibitors are also called "AChE" and "AC" appears in unrelated cardiology contexts. In oncology, AC and TC are strictly breast-cancer adjuvant labels. If you see "AC" in a lab report with "TC" nearby, you are almost certainly looking at a breast oncology plan.

Why anthracyclines and taxanes work differently

Anthracyclines intercalate into DNA and poison topoisomerase II, which generates double-strand breaks. They also generate reactive oxygen species and trigger apoptosis through p53-dependent pathways. This mechanism is cell-cycle nonspecific, meaning it kills cells in any phase of division. That is why AC hits rapidly dividing tissue broadly, including bone marrow and hair follicles.

Taxanes stabilize microtubules instead. They lock tubulin polymers so the mitotic spindle cannot disassemble, which arrests cells in the G2/M transition. This is a spindle poison, and its activity depends on cells actively progressing through mitosis. That single mechanistic difference explains much of the toxicity profile divergence.

Cyclophosphamide, shared by both regimens, is an alkylating prodrug activated by liver cytochrome P450. It crosslinks DNA at guanine N7 positions and is cell-cycle nonspecific. In both AC and TC, cyclophosphamide contributes overlapping myelosuppression.

In plain terms: AC damages DNA directly and indiscriminately, while TC jams the cell's division machinery, and the side effects follow from those two different attack styles.

How the two regimens compare head to head

The table below reconciles the main practical differences. All doses assume standard adjuvant dosing in a 70 kg adult with normal organ function.

The dose-dense AC schedule matters. Giving AC every 14 days with growth factor support rather than every 21 days improves disease-free survival in node-positive disease, based on the landmark CALGB 9741 trial published in 2003. TC has no equivalent validated dose-dense schedule in routine practice.

Toxicity timelines: when each side effect peaks

Both regimens follow predictable toxicity clocks, but the peaks land in different weeks. This timeline table reflects typical grade 2 or higher events in a standard 4-cycle course.

One non-obvious detail: docetaxel's acute arthralgia syndrome is not cumulative and usually peaks in the first 48 to 72 hours after infusion. Many patients mistake it for disease recurrence. In contrast, the neuropathy from docetaxel is cumulative, and its severity tracks total dose rather than any single cycle.

Where the evidence diverges: high-risk disease

The two regimens are not interchangeable in every setting. For node-negative, HER2-negative disease, TC has a strong evidence base from US Oncology trial 9735, published in 2008, which showed TC was non-inferior to AC in disease-free survival over a median follow-up of about 7 years. That trial anchors TC as an acceptable standard when anthracyclines are avoided.

But the picture changes in high-risk disease. A meta-analysis of anthracycline versus non-anthracycline regimens, published in the Journal of Clinical Oncology in 2019 by Early Breast Cancer Trialists' Collaborative Group data, indicated that anthracycline-based regimens retain a modest disease-free survival advantage in higher-risk subgroups, in the range of 2 to 3 percentage points at 10 years. That margin is why many guidelines still favor AC-based regimens for node-positive or triple-negative disease.

The practical inversion is counterintuitive: TC is not "AC without the heart risk." It swaps cardiac exposure for neurologic exposure. In a patient with pre-existing cardiac disease, TC wins. In a patient who needs a manual job without numbness, AC wins.

Misconceptions about AC and TC

The most common misconception is that AC is obsolete. It is not. Anthracyclines remain the backbone in high-risk HER2-negative and triple-negative disease because the 2 to 3 percentage point survival margin is meaningful at a population level. Dropping AC in every patient would cost lives in the high-risk subgroup.

A second misconception is that TC is gentler because it lacks an anthracycline. TC carries real risk: febrile neutropenia in roughly 5 to 10% of patients without growth factor support, plus docetaxel hypersensitivity reactions in about 5 to 10% despite premedication. Cardiac risk is lower, but overall toxicity burden is comparable.

A third error is conflating the "C" in both regimens. The cyclophosphamide dose is identically 600 mg/m² in standard AC and TC, so the shared drug does not differentiate the regimens. The difference lives entirely in the anthracycline-versus-taxane swap.

A fourth mistake concerns the doxorubicin lifetime cap. The roughly 450 to 550 mg/m² cumulative ceiling is for doxorubicin only. At 60 mg/m² per cycle over 4 cycles, a patient reaches 240 mg/m², well under the cap. The cap becomes relevant only if anthracyclines are later re-challenged.

What to actually do before and during treatment

Concrete steps reduce serious complications in both regimens, but the priorities differ by arm.

• Get a baseline echocardiogram or MUGA scan before the first AC cycle, and repeat at the end of treatment; TC does not require routine cardiac monitoring unless the patient has prior cardiac history.
• Ask about primary G-CSF prophylaxis (pegfilgrastim) if you are on dose-dense AC or have any febrile neutropenia risk factor; AC dose-dense schedules and TC both justify it in the appropriate patient.
• For TC, track neuropathy with a simple symptom log weekly and report any new numbness, tingling, or balance change immediately rather than waiting for the next visit.
• For TC, premedicate with dexamethasone as prescribed to reduce docetaxel hypersensitivity and fluid retention; skipping premedication raises the reaction rate.
• For AC, expect reddish-orange urine in the first 24 hours after doxorubicin; it is harmless, but call your team if you also see decreased urine output or swelling.
• Report any fever of 100.4°F (38°C) or higher immediately, regardless of regimen; febrile neutropenia can progress fast.

Red-flag warnings that require urgent care

These warrant same-day contact with the oncology team, not waiting for a scheduled visit.

• Fever of 100.4°F (38°C) or higher, or chills with rigors.
• Shortness of breath at rest, new swelling in the legs, or rapid weight gain of more than 3 pounds in a day, which may signal fluid overload or anthracycline cardiotoxicity.
• Chest pain or palpitations, particularly in the days following an AC infusion.
• New severe numbness, weakness, or inability to walk steadily (a TC neuropathy signal).
• Any sign of extravasation at the infusion site, such as burning, blistering, or redness tracking up the arm.

Limits of the evidence and what remains uncertain

The head-to-head evidence has gaps. No large randomized trial has directly compared AC and TC in the modern era with contemporary HER2-targeted and genomic-risk-guided treatment, so the 2 to 3 percentage point advantage for anthracyclines comes largely from older meta-analyses and indirect comparisons. Genomic assays such as Oncotype DX and MammaPrint are now used to decide who needs chemotherapy at all, which has shrunk the population where AC-versus-TC is even a live question.

The cardiac monitoring thresholds also lack precision. A drop in left ventricular ejection fraction to below 50% or a 10-point absolute decline from baseline are the common cutoffs, but they are consensus thresholds, not trial-validated triggers. The doxorubicin cap of roughly 450 to 550 mg/m² is similarly a convention with wide interpatient variability in real cardiac risk.

Finally, the neuropathy reversibility data for TC are heterogeneous. Reports range from about 10% to 20% residual neuropathy at 12 months, but that range reflects different measurement instruments rather than true biological variation. Patients should treat any persistent neuropathy beyond 12 months as a real possibility, not a statistical outlier.